Balance of chemokine entry and exit signals controls T cell accumulation in skin

趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累

基本信息

  • 批准号:
    7222766
  • 负责人:
  • 金额:
    $ 12.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-04-12 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): With the proposed Research Scientist Development Award, the applicant will build upon her prior experience in antigen and chemokine regulation of T cell migration and immunity to study T cell recirculation using in vivo models of skin inflammation. The laboratory of Andrew D. Luster, MD, PhD, at Massachusetts General Hospital will provide a stimulating environment to further the candidate's scientific development toward achieving her ultimate goal of independent investigation. The proposed study will provide the applicant with the opportunity to examine the interplay of chemokines in regulating the migratory fate of T cells in inflamed skin. Both T cell entry into tissues from the bloodstream and T cell exit from tissues into afferent lymph control the accumulation of lymphocytes at peripheral sites and their participation in immune/inflammatory reactions. The roles of several individual chemokines in directing the traffic of T cell entry and exit from the skin have been characterized. However, the interplay between different chemokine signals in controlling the transit of T cells through skin remains completely unknown. Here, we hypothesize that a balance in chemokine entry, retention, and exit signals regulates the accumulation of effector/memory T cells within skin. In these proposed studies, we will use delayed type hypersensitivity and allergic dermatitis models to 1) Investigate the mechanisms that regulate the accumulation of effector/memory T cells in inflamed skin. We will track the migration of responding T cells by labelling cutaneous T cells in vivo with CFSE and determine the chemokine receptor expression profiles of CFSE+ T cells that remain in the skin, versus those that continue to migrate through the skin to draining lymph nodes; 2) Determine the consequence of effector/memory T cell antigen recognition in peripheral tissues on their expression of chemokine receptors and their retention in skin versus migration into afferent lymph; 3) Attempt to override the balance in chemokine receptor responsiveness using genetically altered T cells and mice that either lack or overexpress chemokine receptors or chemokine ligands. Results from these studies should further elucidate the mechanisms that regulate T cell transit through tissues and might benefit the treatment of pathological conditions in which large T cell infiltrates accumulate inappropriately in peripheral tissues.
描述(由申请者提供):通过建议的研究科学家发展奖,申请者将以她在T细胞迁移和免疫的抗原和趋化因子调节方面的先前经验为基础,利用皮肤炎症的活体模型来研究T细胞再循环。马萨诸塞州总医院安德鲁·D·卢斯特博士的实验室将提供一个刺激的环境,促进候选人的科学发展,实现她独立研究的最终目标。这项拟议的研究将为申请者提供机会来研究趋化因子在调节发炎皮肤中T细胞迁移命运方面的相互作用。 T细胞从血液进入组织和T细胞从组织进入传入淋巴都控制着淋巴细胞在外周部位的聚集及其参与免疫/炎症反应。几种单独的趋化因子在引导T细胞进入和离开皮肤的交通中的作用已经被表征。然而,不同的趋化因子信号之间在控制T细胞通过皮肤转运方面的相互作用仍然完全不清楚。这里,我们假设趋化因子进入、保留和退出信号的平衡调节效应/记忆T细胞在皮肤内的积累。在这些拟议的研究中,我们将使用迟发型超敏反应和过敏性皮炎模型来1)研究调节炎症皮肤中效应/记忆T细胞积累的机制。我们将通过用CFSE标记活体皮肤T细胞来跟踪反应性T细胞的迁移,并确定CFSE+T细胞与那些继续通过皮肤迁移到引流淋巴结的CFSE+T细胞的趋化因子受体表达谱;2)确定外周组织中效应/记忆T细胞抗原识别对其趋化因子受体表达的影响,以及它们在皮肤中的滞留与向传入淋巴的迁移;3)尝试使用基因改变的T细胞和缺乏或过度表达趋化因子受体或趋化因子配体的小鼠来打破趋化因子受体反应性的平衡。这些研究的结果将进一步阐明调节T细胞在组织中转运的机制,并可能有助于治疗大量T细胞在周围组织中不当积聚的病理情况。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHANNON K BROMLEY其他文献

SHANNON K BROMLEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHANNON K BROMLEY', 18)}}的其他基金

Effect of Th2-type microenvironment on CD8 TRM-mediated protection from infection
Th2型微环境对CD8 TRM介导的感染保护作用的影响
  • 批准号:
    10624943
  • 财政年份:
    2022
  • 资助金额:
    $ 12.85万
  • 项目类别:
Effect of allergic asthma on CD8+ TRM-mediated protection from infection
过敏性哮喘对 CD8 TRM 介导的感染保护作用的影响
  • 批准号:
    10495217
  • 财政年份:
    2021
  • 资助金额:
    $ 12.85万
  • 项目类别:
Effect of allergic asthma on CD8+ TRM-mediated protection from infection
过敏性哮喘对 CD8 TRM 介导的感染保护作用的影响
  • 批准号:
    10353929
  • 财政年份:
    2021
  • 资助金额:
    $ 12.85万
  • 项目类别:
Mechanisms of CD49a Expression and Resident Memory T Cell Formation in Skin.
皮肤中 CD49a 表达和常驻记忆 T 细胞形成的机制。
  • 批准号:
    9302659
  • 财政年份:
    2016
  • 资助金额:
    $ 12.85万
  • 项目类别:
Bromley Pilot and Feasibility Project
布罗姆利试点和可行性项目
  • 批准号:
    7393279
  • 财政年份:
    2007
  • 资助金额:
    $ 12.85万
  • 项目类别:
Balance of chemokine entry and exit signals controls T cell accumulation in skin
趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累
  • 批准号:
    7590369
  • 财政年份:
    2006
  • 资助金额:
    $ 12.85万
  • 项目类别:
Balance of chemokine entry and exit signals controls T cell accumulation in skin
趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累
  • 批准号:
    7393238
  • 财政年份:
    2006
  • 资助金额:
    $ 12.85万
  • 项目类别:
Balance of chemokine entry and exit signals controls T cell accumulation in skin
趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累
  • 批准号:
    7789488
  • 财政年份:
    2006
  • 资助金额:
    $ 12.85万
  • 项目类别:
Balance of chemokine entry and exit signals controls T cell accumulation in skin
趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累
  • 批准号:
    7085722
  • 财政年份:
    2006
  • 资助金额:
    $ 12.85万
  • 项目类别:
CCR7 and CCR9 in T Cell Development and Trafficking
T 细胞发育和运输中的 CCR7 和 CCR9
  • 批准号:
    6695301
  • 财政年份:
    2003
  • 资助金额:
    $ 12.85万
  • 项目类别:

相似海外基金

Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
在临床前小鼠和非人灵长类动物模型中确定 A 组链球菌疫苗抗原最有效的佐剂
  • 批准号:
    10577066
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
  • 批准号:
    10522591
  • 财政年份:
    2022
  • 资助金额:
    $ 12.85万
  • 项目类别:
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
  • 批准号:
    10884052
  • 财政年份:
    2022
  • 资助金额:
    $ 12.85万
  • 项目类别:
Establishment of postoperative adjuvant immunotherapy using peptide pool of tumor antigens in advanced esophageal cancer
晚期食管癌肿瘤抗原肽库术后辅助免疫治疗的建立
  • 批准号:
    15K10100
  • 财政年份:
    2015
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of cancer vaccine using adjuvant function encrypted artificial antigens
使用佐剂功能加密人工抗原开发癌症疫苗
  • 批准号:
    26430172
  • 财政年份:
    2014
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
  • 批准号:
    7849955
  • 财政年份:
    2009
  • 资助金额:
    $ 12.85万
  • 项目类别:
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
  • 批准号:
    7627172
  • 财政年份:
    2009
  • 资助金额:
    $ 12.85万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    2068228
  • 财政年份:
    1992
  • 资助金额:
    $ 12.85万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    3548034
  • 财政年份:
    1992
  • 资助金额:
    $ 12.85万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    3548033
  • 财政年份:
    1992
  • 资助金额:
    $ 12.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了